Latent Tuberculosis Infection Testing Market

The Latent Tuberculosis Infection (LTBI) Testing industry can be broken down into several segments, Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA), etc.

Across the world, the major players cover Qiagen, Oxford Immunotec, Sanofi, etc.

Diagnosing and treating latent tuberculosis (TB) infection (LTBI) is recognized by the World Health Organization as an important strategy to accelerate the decline in global TB and achieve TB elimination. Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically manifested active tuberculosis (TB). Diagnosis and treatment for LTBI are important for TB, especially in high-risk populations. Tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) are used to diagnose LTBI.

Latent Tuberculosis Infection Testing Market contains market size and forecasts of Latent Tuberculosis Infection (LTBI) Testing in Global, including the following market information:

Global Latent Tuberculosis Infection (LTBI) Testing Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Latent Tuberculosis Infection (LTBI) Testing market was valued at 1436.4 million in 2021 and is projected to reach US$ 2043.9 million by 2028, at a CAGR of 5.2% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Tuberculin Skin Test (TST) Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Latent Tuberculosis Infection (LTBI) Testing include Qiagen, Sanofi, Oxford Immunotec, Thermo Fisher Scientific, Par Sterile and Bio-Rad Laboratories, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Latent Tuberculosis Infection (LTBI) Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Latent Tuberculosis Infection (LTBI) Testing Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Latent Tuberculosis Infection (LTBI) Testing Market Segment Percentages, by Type, 2021 (%)

Tuberculin Skin Test (TST)

Interferon Gamma Released Assay (IGRA)

Global Latent Tuberculosis Infection (LTBI) Testing Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Latent Tuberculosis Infection (LTBI) Testing Market Segment Percentages, by Application, 2021 (%)

Hospitals and Clinics

Diagnostic Laboratories

Others

Global Latent Tuberculosis Infection (LTBI) Testing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Latent Tuberculosis Infection (LTBI) Testing Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Latent Tuberculosis Infection (LTBI) Testing revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Latent Tuberculosis Infection (LTBI) Testing revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Qiagen

Sanofi

Oxford Immunotec

Thermo Fisher Scientific

Par Sterile

Bio-Rad Laboratories